|
|
|
|
| LEADER |
03592nmm a2200361 u 4500 |
| 001 |
EB001901353 |
| 003 |
EBX01000000000000001064262 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
200911 ||| eng |
| 020 |
|
|
|a 9783030430856
|
| 100 |
1 |
|
|a Kleinerman, Eugenie S.
|e [editor]
|
| 245 |
0 |
0 |
|a Current Advances in the Science of Osteosarcoma
|h Elektronische Ressource
|b Research Perspectives: Tumor Biology, Organ Microenvironment, Potential New Therapeutic Targets, and Canine Models
|c edited by Eugenie S. Kleinerman, Richard Gorlick
|
| 250 |
|
|
|a 2nd ed. 2020
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2020, 2020
|
| 300 |
|
|
|a XIII, 233 p. 34 illus., 23 illus. in color
|b online resource
|
| 505 |
0 |
|
|a The genomic complexity of osteosarcoma and its implication for preclinical and clinical targeted therapies -- Genomics and the Immune Landscape of Osteosarcoma -- RECQ DNA Helicases and Osteosarcoma -- Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma -- Oncolytic viruses and their potential as a therapeutic opportunity in Osteosarcoma -- Applying Osteosarcoma Immunology to Understand Disease Progression and Assess immunotherapeutic Response -- Targetable intercellular signaling pathways facilitate lung colonization in osteosarcoma -- Wnt Signaling in Osteosarcoma -- Receptor Tyrosine Kinases in Osteosarcoma: 2019 update -- The Role of ALDH in the Metastatic Potential of Osteosarcoma Cells and Potential ALDH Targets -- Autophagy in OS -- Fas signaling as a potential target for the treatment of osteosarcoma metastasis in the lungs -- Exosomes: Dynamic Mediators of Extracellular Communication in the TumorMicroenvironment -- Comparative Immunology and Immunotherapy of Canine Osteosarcoma -- Index
|
| 653 |
|
|
|a Cell Biology
|
| 653 |
|
|
|a Cytology
|
| 653 |
|
|
|a Cancer
|
| 653 |
|
|
|a Medical Microbiology
|
| 653 |
|
|
|a Cancer Biology
|
| 653 |
|
|
|a Medical microbiology
|
| 653 |
|
|
|a Pediatrics
|
| 700 |
1 |
|
|a Gorlick, Richard
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Advances in Experimental Medicine and Biology
|
| 028 |
5 |
0 |
|a 10.1007/978-3-030-43085-6
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-030-43085-6?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 082 |
0 |
|
|a 571.978
|
| 520 |
|
|
|a This thoroughly revised second edition is an up-to-date overview of the new advances in the knowledge of the basic science in sarcoma and osteosarcoma. It features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, this essential volume also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists
|